Developer docs
API playgroundTry for free, no card

Search company profiles

VitaDX

Full company profile

uuid0000qii

Namestring
VitaDX
Legal namestring
VitaDx International (VitaDx)
Websiteurl
vitadx.com
Company typeenum
Private
Founded yearint
2015
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI cancer diagnostics, cytology analysis software, bladder cancer detection, in vitro diagnostics, medical imaging AI
Industry4 codes
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAD
Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAM
DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
AI Cancer Diagnostics Software
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Diagnostic Testing Services
TypeTransaction Fee
Description

VitaDX generates revenue through the sale of VisioCyt® Bladder diagnostic tests to healthcare facilities and laboratory networks. The test is covered under the French RIHN 2.0 program at 100% for patients enrolled in the TVNIM registry, with a patient contribution of 253 euros for routine prescriptions.

vitadx.com
2Technology Licensing
TypeLicensing Royalties
Description

The company licenses its VisioCyt® technology platform for different cancer applications, including the ongoing development partnership with MEDIPATH for thyroid cancer diagnosis under the France 2030 program.

vitadx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details2 tiers
1RIHN 2.0 Coverage - Registry patients
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

Full coverage (100%) under the national RIHN 2.0 device for patients enrolled in the AFU TVNIM registry, with structured real-world data collection.

vitadx.com
2Routine Clinical Practice
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

Patient contribution of 253 euros for test prescription outside the registry framework. Analysis is not reimbursed by the national health insurance system.

vitadx.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1VisioCyt®
Description

AI-powered technology platform using deep learning and computer vision algorithms to analyze and diagnose digitized cytology slides for cancer detection

vitadx.com
+3 more records
Core offering1 text field

VitaDX develops and commercializes AI-powered diagnostic solutions applied to cytology through its proprietary VisioCyt® deep learning platform. The company sells VisioCyt® Bladder, a CE IVDR Class C in vitro diagnostic medical device that analyzes digitized urine cytology slides to detect and monitor urothelial carcinoma. The technology is also being extended to thyroid cancer diagnosis and asymptomatic bladder cancer screening applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Mean sensitivity: 80.9%; Sensitivity for high-grade cancer: 93.7%; Sensitivity for low-grade cancer: 66.7%; Specificity: 61.8%
+1 more record
Product overview1 text field

VitaDX develops and commercializes cancer diagnostic solutions combining image analysis and artificial intelligence applied to cytology through its proprietary VisioCyt® technology platform. The core product VisioCyt® Bladder (CE IVDR Class C) is a commercialized solution for bladder cancer diagnosis and monitoring from urine samples. Two additional products are in development: VisioCyt® Screening for bladder cancer screening in high-risk asymptomatic patients, and VisioCyt® Thyroid for thyroid cancer diagnosis from fine-needle aspiration. All products use deep learning and computer vision algorithms to analyze digitized cytology slides, with VisioCyt® Bladder showing mean sensitivity of 80.9% and 93.7% sensitivity for high-grade cancers.

Product and service3 records
1VisioCyt® Bladder
CategoryAI Diagnostic Medical Device
Description

CE IVDR Class C in vitro diagnostic medical device that performs automated cytology analysis on digitized urine samples using deep learning algorithms to detect and classify urothelial carcinoma cells for diagnosis and surveillance of bladder cancer. Mean sensitivity of 80.9% with 93.7% sensitivity for high-grade cancers.

2VisioCyt® Screening
CategoryAI Diagnostic Software (in development)
Description

AI-powered bladder cancer screening test in development for asymptomatic, high-risk patients, addressing the current absence of a screening test for bladder cancer.

3VisioCyt® Thyroid
CategoryAI Diagnostic Software (in development)
Description

AI-based diagnostic test in development for thyroid cancer detection from fine-needle aspiration samples, developed in collaboration with MEDIPATH under the France 2030 program.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-01
Description

AFU is deploying a national registry for TVNIM (non-muscle-invasive bladder tumors) to collect real-world patient data. VitaDX's VisioCyt® Bladder is integrated as one of four diagnostic tests being evaluated in the registry protocol. The partnership enables structured clinical data collection supporting reimbursement applications and provides access to urology practices across France for test distribution.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-01-01
Description

Strategic partnership with Biogroup, one of France's largest networks of medical biology laboratories with over 900 locations, to expand urine sample collection points for VisioCyt® Bladder testing. Patients can have their samples collected at Biogroup laboratories and prescribed by participating urologists in the TVNIM registry.

3Pfizer Healthcare Hub France
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-01-01
Description

Selected among 5 startups for the Pfizer Healthcare Hub France program, providing 9 months of customized dual mentorship with a Pfizer pharmaceutical industry expert and a WILCO entrepreneurship mentor to accelerate development and market access.

vitadx.com
Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-01-01
Description

WILCO provides startup acceleration services and entrepreneurship mentorship as part of the Pfizer Healthcare Hub France program, supporting VitaDX's business development and go-to-market strategy.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Collaboration with MEDIPATH, independent group of pathologists specializing in cancer diagnosis and proximity expertise, for deployment of VisioCyt® for early bladder cancer diagnosis. Additionally, joint development of VisioCyt® Thyroid under the France 2030 medical imaging program, where MEDIPATH provides pathology expertise and clinical validation infrastructure.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-based digital pathology platform for cancer diagnosis using deep learning on whole-slide images. Directly comparable as a SaMD for AI-driven cancer detection from digitized pathology slides, with overlapping technology and customer base (pathology labs, hospitals).

TypeDirect peer
Description

AI-powered cancer diagnostics platform for pathology, including prostate and breast cancer detection from biopsy slides. Closely comparable as an AI pathology company targeting hospital and laboratory workflows with regulatory-cleared diagnostic software.

TypeDirect peer
Description

AI-powered pathology platform for both diagnostic and drug development applications. Comparable as a deep-learning pathology company with similar technology stack and customer overlap with anatomopathology laboratories.

TypeDirect peer
Description

Developer of Cxbladder, a non-invasive urine-based diagnostic test for bladder cancer detection and monitoring. Direct clinical-area peer, addressing the same bladder cancer surveillance use case that VitaDX's VisioCyt® Bladder targets.

TypeBroad incumbent
Description

French-founded AI diagnostics and drug discovery company with broader oncology portfolio spanning pathology, multimodal AI, and biopharma partnerships. Comparable technology stack and French/EU footprint, but with broader scope beyond cytology.

TypeBroad incumbent
Description

Korean AI medical imaging company with FDA-cleared products for cancer detection (notably Lunit INSIGHT for mammography and Lunit SCOPE for pathology). Comparable as a publicly listed AI diagnostics player with similar deep-learning + imaging approach but broader modality coverage.

TypeEmerging player
Description

Hamburg-based AI pathology startup offering deep-learning-based analysis tools for pathology labs including IHC quantification and cell detection. Comparable as an EU AI pathology player targeting laboratory workflows, with overlapping customer profile but smaller scale.

TypeEmerging player
Description

Israel-based AI spatial biology and pathology company providing tumor microenvironment analysis from H&E and multiplexed images. Comparable as an AI pathology company with similar deep-learning approach, but focused on spatial biology research applications rather than routine IVD diagnostics.

TypeEmerging player
Description

Developer of Oncuria, a non-invasive multiplex urine biomarker test for bladder cancer detection and monitoring. Direct clinical-area peer in bladder cancer diagnostics with a complementary (protein biomarker) but overlapping product approach.

10Tempus Labs
TypeBroad incumbent
Description

US-based technology company combining AI with multi-modal data (imaging, molecular, clinical) for precision oncology. Comparable as an AI-driven cancer diagnostics platform, but at significantly larger scale with broader indications including pathology.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

VitaDX

AI Cancer Diagnostics Softwarevitadx.com

VitaDX firmographics

Firmographics
Name
VitaDX
Legal name
VitaDx International (VitaDx)
Website
https://vitadx.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

VitaDX industry classification

Industry
Product category
AI Cancer Diagnostics Software
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAD
Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAM
DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI

Keywords

  • AI cancer diagnostics
  • Cytology analysis software
  • Bladder cancer detection
  • In vitro diagnostics
  • Medical imaging AI

Where VitaDX is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices2 records

Markets served

VitaDX business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Diagnostic Testing Services: VitaDX generates revenue through the sale of VisioCyt® Bladder diagnostic tests to healthcare facilities and laboratory networks. The test is covered under the French RIHN 2.0 program at 100% for patients enrolled in the TVNIM registry, with a patient contribution of 253 euros for routine prescriptions.
  2. Technology Licensing: The company licenses its VisioCyt® technology platform for different cancer applications, including the ongoing development partnership with MEDIPATH for thyroid cancer diagnosis under the France 2030 program.

Pricing tiers

ModelBillingPrice
Transaction based/ take ratePay-as-you-goRIHN 2.0 Coverage - Registry patients
Transaction based/ take ratePay-as-you-goRoutine Clinical Practice

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

VitaDX product offering

Product offering

Core offering

VitaDX develops and commercializes AI-powered diagnostic solutions applied to cytology through its proprietary VisioCyt® deep learning platform. The company sells VisioCyt® Bladder, a CE IVDR Class C in vitro diagnostic medical device that analyzes digitized urine cytology slides to detect and monitor urothelial carcinoma. The technology is also being extended to thyroid cancer diagnosis and asymptomatic bladder cancer screening applications.

Product overview

VitaDX develops and commercializes cancer diagnostic solutions combining image analysis and artificial intelligence applied to cytology through its proprietary VisioCyt® technology platform. The core product VisioCyt® Bladder (CE IVDR Class C) is a commercialized solution for bladder cancer diagnosis and monitoring from urine samples. Two additional products are in development: VisioCyt® Screening for bladder cancer screening in high-risk asymptomatic patients, and VisioCyt® Thyroid for thyroid cancer diagnosis from fine-needle aspiration. All products use deep learning and computer vision algorithms to analyze digitized cytology slides, with VisioCyt® Bladder showing mean sensitivity of 80.9% and 93.7% sensitivity for high-grade cancers.

Differentiator

Problem solved

Functional benefit

Brands

  • VisioCyt®: AI-powered technology platform using deep learning and computer vision algorithms to analyze and diagnose digitized cytology slides for cancer detection
  • VisioCyt® Bladder
  • VisioCyt® Screening
  • VisioCyt® Thyroid

Products and services

  • VisioCyt® Bladder CE IVDR Class C in vitro diagnostic medical device that performs automated cytology analysis on digitized urine samples using deep learning algorithms to detect and classify urothelial carcinoma cells for diagnosis and surveillance of bladder cancer. Mean sensitivity of 80.9% with 93.7% sensitivity for high-grade cancers.
  • VisioCyt® Screening AI-powered bladder cancer screening test in development for asymptomatic, high-risk patients, addressing the current absence of a screening test for bladder cancer.
  • VisioCyt® Thyroid AI-based diagnostic test in development for thyroid cancer detection from fine-needle aspiration samples, developed in collaboration with MEDIPATH under the France 2030 program.

Quantifiable outcome

  • Mean sensitivity: 80.9%; Sensitivity for high-grade cancer: 93.7%; Sensitivity for low-grade cancer: 66.7%; Specificity: 61.8%
  • +1 more outcomes

Companies that use VitaDX

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles2 records

VitaDX technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

VitaDX partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Association Française d'Urologie (AFU)coreStrategic or Co-development Partner · 1 May 2025AFU is deploying a national registry for TVNIM (non-muscle-invasive bladder tumors) to collect real-world patient data. VitaDX's VisioCyt® Bladder is integrated as one of four diagnostic tests being evaluated in the registry protocol. The partnership enables structured clinical data collection supporting reimbursement applications and provides access to urology practices across France for test distribution.
  • BiogroupcoreChannel Partner/ Reseller/ Distributor · 1 January 2025Strategic partnership with Biogroup, one of France's largest networks of medical biology laboratories with over 900 locations, to expand urine sample collection points for VisioCyt® Bladder testing. Patients can have their samples collected at Biogroup laboratories and prescribed by participating urologists in the TVNIM registry.
  • Pfizer Healthcare Hub FranceminorGTM or Marketing Partner · 1 January 2025Selected among 5 startups for the Pfizer Healthcare Hub France program, providing 9 months of customized dual mentorship with a Pfizer pharmaceutical industry expert and a WILCO entrepreneurship mentor to accelerate development and market access.
  • WILCOminorImplementation/ SI/ Consulting Partner · 1 January 2025WILCO provides startup acceleration services and entrepreneurship mentorship as part of the Pfizer Healthcare Hub France program, supporting VitaDX's business development and go-to-market strategy.
  • MEDIPATH FrancecoreStrategic or Co-development Partner · 1 January 2023Collaboration with MEDIPATH, independent group of pathologists specializing in cancer diagnosis and proximity expertise, for deployment of VisioCyt® for early bladder cancer diagnosis. Additionally, joint development of VisioCyt® Thyroid under the France 2030 medical imaging program, where MEDIPATH provides pathology expertise and clinical validation infrastructure.

Scale indicators4 records

Recent moves6 records

Expansion highlights7 records

VitaDX competitors and assessment

Company assessment

Direct peers

  • Paige.AI: AI-based digital pathology platform for cancer diagnosis using deep learning on whole-slide images. Directly comparable as a SaMD for AI-driven cancer detection from digitized pathology slides, with overlapping technology and customer base (pathology labs, hospitals).
  • Ibex Medical Analytics: AI-powered cancer diagnostics platform for pathology, including prostate and breast cancer detection from biopsy slides. Closely comparable as an AI pathology company targeting hospital and laboratory workflows with regulatory-cleared diagnostic software.
  • PathAI: AI-powered pathology platform for both diagnostic and drug development applications. Comparable as a deep-learning pathology company with similar technology stack and customer overlap with anatomopathology laboratories.
  • Pacific Edge Diagnostics: Developer of Cxbladder, a non-invasive urine-based diagnostic test for bladder cancer detection and monitoring. Direct clinical-area peer, addressing the same bladder cancer surveillance use case that VitaDX's VisioCyt® Bladder targets.

Broad incumbents

  • Owkin: French-founded AI diagnostics and drug discovery company with broader oncology portfolio spanning pathology, multimodal AI, and biopharma partnerships. Comparable technology stack and French/EU footprint, but with broader scope beyond cytology.
  • Lunit: Korean AI medical imaging company with FDA-cleared products for cancer detection (notably Lunit INSIGHT for mammography and Lunit SCOPE for pathology). Comparable as a publicly listed AI diagnostics player with similar deep-learning + imaging approach but broader modality coverage.
  • Tempus Labs: US-based technology company combining AI with multi-modal data (imaging, molecular, clinical) for precision oncology. Comparable as an AI-driven cancer diagnostics platform, but at significantly larger scale with broader indications including pathology.

Emerging players

  • Mindpeak: Hamburg-based AI pathology startup offering deep-learning-based analysis tools for pathology labs including IHC quantification and cell detection. Comparable as an EU AI pathology player targeting laboratory workflows, with overlapping customer profile but smaller scale.
  • Nucleai: Israel-based AI spatial biology and pathology company providing tumor microenvironment analysis from H&E and multiplexed images. Comparable as an AI pathology company with similar deep-learning approach, but focused on spatial biology research applications rather than routine IVD diagnostics.
  • Nonagen Bioscience: Developer of Oncuria, a non-invasive multiplex urine biomarker test for bladder cancer detection and monitoring. Direct clinical-area peer in bladder cancer diagnostics with a complementary (protein biomarker) but overlapping product approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

VitaDX social profiles

Digital presence

VitaDX compliance and trust

Trust signal

Compliance1 record

VitaDX financial estimates

Financial estimate

Revenue estimate

Valuation estimate

VitaDX leadership team

Management profile

Number of profiles

Profiles9 records

VitaDX funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

VitaDX M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VitaDX

What does VitaDX do?

VitaDX develops and commercializes AI-powered diagnostic solutions applied to cytology through its proprietary VisioCyt® deep learning platform. The company sells VisioCyt® Bladder, a CE IVDR Class C in vitro diagnostic medical device that analyzes digitized urine cytology slides to detect and monitor urothelial carcinoma. The technology is also being extended to thyroid cancer diagnosis and asymptomatic bladder cancer screening applications.

Is VitaDX a public or private company?

VitaDX is a private company. It is classified as venture growth investor backed and is currently operating.

When was VitaDX founded?

VitaDX was founded in 2015. It employs 11 to 50 people.

Where is VitaDX based?

VitaDX is headquartered in Paris, France, in the Europe region.

How does VitaDX make money?

Two revenue lines are on record. Diagnostic Testing Services are the primary driver. The others are technology Licensing.

Who are VitaDX's main competitors?

Direct peers on record are Paige.AI, Ibex Medical Analytics, PathAI and Pacific Edge Diagnostics. Broad incumbents are Owkin, Lunit and Tempus Labs. Emerging players are Mindpeak, Nucleai and Nonagen Bioscience.

Does VitaDX have an API?

No public API is recorded for VitaDX.

What industry is VitaDX in?

VitaDX's product category is AI Cancer Diagnostics Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HLACANAD, Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software. Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals